October 2, 2025Frontiers in ImmunologyOpen Access

Metabolic-immune axis in the tumor microenvironment: a new strategy for prognostic assessment and precision therapy in DLBCL and FL

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Analysis reveals metabolic-immune interactions affecting prognosis in DLBCL and FL, suggesting integrated therapies.

Elevated tumor metabolic volume correlates with aggressive disease and poor outcomes in DLBCL and FL.
High tumor-infiltrating lymphocyte density often predicts better treatment responses in lymphoma patients.
Integrating metabolic and immune biomarkers enhances risk stratification for precision therapy in lymphoma.
Combining metabolic inhibitors with immunotherapies may significantly improve treatment outcomes for these lymphomas.

Chen et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark